ArticleInternational journal of clinical and experimental medicine2015
Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis.PloS one · 2016Pooled it
- A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India.Cancer informatics · 2023Article
- Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?Molecular therapy oncolytics · 2021Review
- Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer.OncoTargets and therapy · 2018Review
- The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials.Oncotarget · 2017Article
- Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation ofJCO precision oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality worldwide. Bevacizumab plays an important role in the treatment of metastatic CRC (mCRC). The aim of this study was to evaluate the efficacy and safety of chemotherapy plus bevacizumab as first-line treatment in patients with mCRC. Randomized-controlled clinical trials comparing the efficacy of chemotherapy plus bevacizumab or chemotherapy alone in patients with mCRC were searched using the following electronic database of PubMed, Medline, Embase and CNKI. Total 9 trials, containing 1843 patients in chemotherapy plus bevacizumab group and 1741 patients in chemotherapy alone group, were included. Our results showed that chemotherapy plus bevacizumab statistically increased the Overall response rate (ORR) in patients with mCRC (OR = 1.57, 95% CI = 1.17-2.11, P = 0.003) in a random-effects model. The complete response rate and partial response rate were statistically increased as well (P ≤ 0.05). Subgroup analysis by bevacizumab dosage found that bevacizumab 5 mg/kg statistically increased the ORR. Significant differences were found in PFS (HR = 0.56, 95% CI = 0.46-0.69, P < 0.00001) and OS (HR = 0.83, 95% CI = 0.76-0.91, P < 0.0001) as well. No significant difference was found in adverse events. Overall, the combination of chemotherapy and bevacizumab as first-line treatment is an effective and well-tolerated regimen for patients with mCRC.
Indexed as
Identifiers
25785152PMC4358607What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.